Affecting the nervous system, immune system and other body organs, ataxia telangiectasia is characterized with uncoordinated movements of the individual suffering from this disorder. The secondary ...

Hereditary hemorrhagic telangiectasia, or Osler–Weber–Rendu syndrome, is an autosomal dominant vascular disorder that affects multiple systems. It is characterized by skin and mucosal telangiectasias ...

Please provide your email address to receive an email when new articles are posted on . The NT-501 implant demonstrated positive results in two replicative phase 3 clinical trials for the treatment of ...

Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the ...

IMMUNOLOGIC abnormalities, including hypogammaglobulinemia, abnormalities of gamma 1 A globulin, poor homograft rejection and structural abnormalities of the thymus gland, have recently been reported ...

The Food and Drug Administration (FDA) has extended the review period for the Biologics License Application (BLA) for NT-501 (revakinagene taroretcel) in the treatment of macular telangiectasia type 2 ...

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the poster ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. WAILEA, Hawaii —NT-501, an encapsulated cell therapy for ...

Hereditary hemorrhagic telangiectasia, also known as Rendu–Osler–Weber syndrome, is a disorder inherited as an autosomal dominant trait, characterized by epistaxis, mucocutaneous telangiectasias, and ...

An IgE deficiency was demonstrated in 11 of 16 patients with ataxia-telangiectasia. No relation to age or to the level of IgG, IgM or IgD was found. Nine out of 11 patients with IgE and IgA deficiency ...

Quince Therapeutics’ lead asset eDSP failed to meet the primary or secondary endpoints in the pivotal NEAT trial.